Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2003

View Archived Issues

Elan makes progress through recovery plan

ALT-711 to be further developed based on encouraging safety and efficacy data

Brand name chosen for ABI-007

PhotoPoint PDT may provide benefit in coronary and peripheral atherosclerotic disease

Ligand completes enrollment in pivotal study of Targretin in NSCLC

Corixa initiates phase I clinical study for NSCLC vaccine

New 5-HT2B antagonists and their use in GI disorders described by Pharmagene

Ono claims novel MBR antagonists with utility in stress-related conditions

Kyowa Hakko patent covers new adenosine A2A antagonists, their preparation and use

New PARP inhibitors in early development at Fujisawa

Galileo scientists identify novel compounds with potential in oxidative stress-related disorders

Cytokine production inhibitors prepared and tested by Ishihara Sangyo team

IsoTis signs licensing agreement for Allox

Graffinity and Genentech to collaborate on small-molecule therapeutics

Metabolex to finance phase II trials of its insulin sensitizer MBX-102

Melatonin effective for headache syndromes

Beneficial effects described for valdecoxib in patients with migraine

Clinical benefits of long-term botulinum toxin type A in chronic migraine

Increased expression of constitutive proteins in burned children treated with oxandrolone

Donepezil produces cognitive and functional improvement in vascular dementia

In vitro efficacy of tigecycline, a novel glycylcycline, against Eikenella corrodens

Alpha2-adrenoceptor antagonist effective in a primate model of Parkinson's disease

DX-619, a des-F(6)-quinolone antibiotic with enhanced antistaphylococcal activity

DepoMed enters into termination agreement with Elan

DanioLabs and Oxagen enter collaborative agreement for IBD

European Commission approval granted for Ventavis

Dual thrombin/factor Xa inhibitors evaluated as anticoagulants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...